&lt;p&gt;Resistance To First-Line Antituberculosis Drugs And Prevalence Of &lt;em&gt;pncA&lt;/em&gt; Mutations In Clinical Isolates Of &lt;em&gt;Mycobacterium tuberculosis&lt;/em&gt; From Zunyi, Guizhou Province Of China&lt;/p&gt;

Cao, Zhen-Dong; Lan, Yuanbo; Chen, Ling; Xiang, Min; Peng, Zhiyuan; Zhang, Jianyong; Zhang, Hong

doi:10.2147/idr.s222943

Cited by 9 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result was in line with a study conducted in Belarus, Iran, which showed that the most common age group found in patients with first-line OAT resistance was the 25-44 year age group with 318 patients (34%) (Surkova et al, 2012). This result was also under a study by Cao et al (2019) in China, which showed that patients with the highest number of first-line Anti-TB drugs resistance were 35-55 years with 72 patients (39%). Based on the explanation above, it could be seen that the highest age group was found in the working-age group.…”

Section: Characteristics Of Drug-resistant Tb Patientssupporting

confidence: 88%

Diabetes Mellitus and History of Tuberculosis Treatment as Risk Factors of Developing Multidrug-Resistant Tuberculosis at TB Polyclinic Dr. Soetomo General Hospital 2019 - 2020

Habibi

Bakhtiar²,

Indiastuti³

et al. 2022

JIUBJ

View full text Add to dashboard Cite

Multidrug-Resistant Tuberculosis (MDR TB) is a condition when Mycobacterium tuberculosis were resistant to Isoniazid and Rifampicin simultaneously, with or without being followed by other first-line Anti-Tuberculosis Drugs. Diabetic patients who also have TB are more susceptible to drug resistance. There is ample evidence noting that a history of previous TB treatment is one of the main factors contributing to the development of MDR TB. This study was a case-control study. The sample of this study was all patients from TB Polyclinic Dr. Soetomo Hospital who were diagnosed with pulmonary TB by pulmonologists on January 1, 2019 – December 31, 2020, who met the inclusion criteria. The data obtained were analyzed using the IBM SPSS Statistics 23 application with a binary logistic regression test.There were 178 samples of this study. MDR TB (65.8%) was the dominant resistance type in Drug-Resistant Tuberculosis (DR TB) patients. Patients with DM were 2.2 times more likely to develop MDR TB than patients without DM. Patients with histories of previous tuberculosis (TB) treatment tended to be three times more likely to develop MDR TB than new patients. Other factors such as age, sex, BMI, history of alcohol consumption, and history of smoking did not show a significant relationship with the incidence of MDR TB. Diabetes Mellitus comorbidity and history of previous Tuberculosis treatment were significant risk factors for developing MDR TB.

show abstract

Section: Characteristics Of Drug-resistant Tb Patientssupporting

confidence: 88%

Diabetes Mellitus and History of Tuberculosis Treatment as Risk Factors of Developing Multidrug-Resistant Tuberculosis at TB Polyclinic Dr. Soetomo General Hospital 2019 - 2020

Habibi

Bakhtiar²,

Indiastuti³

et al. 2022

JIUBJ

View full text Add to dashboard Cite

show abstract

“…Although preventable and treatable, with 1.5 million deaths every year, TB is still on the world’s top list of infectious killer diseases [ 1 ]. Furthermore, with the advent of multidrug-resistant tuberculosis (MDR-TB), first-line drugs have been rendered ineffective [ 2 , 3 ]. An estimated 10 million active TB cases were recorded in 2020, which consisted of 5.6 million men, 3.3 million women, and 1.1 million children [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Integrating tuberculosis and noncommunicable diseases care in low- and middle-income countries (LMICs): A systematic review

et al. 2022

View full text Add to dashboard Cite

Background Low- and middle-income countries (LMICs) are facing a combined affliction from both tuberculosis (TB) and noncommunicable diseases (NCDs), which threatens population health and further strains the already stressed health systems. Integrating services for TB and NCDs is advantageous in tackling this joint burden of diseases effectively. Therefore, this systematic review explores the mechanisms for service integration for TB and NCDs and elucidates the facilitators and barriers for implementing integrated service models in LMIC settings. Methods and findings A systematic search was conducted in the Cochrane Library, MEDLINE, Embase, PubMed, Bibliography of Asian Studies, and the Global Index Medicus from database inception to November 4, 2021. For our search strategy, the terms “tuberculosis” AND “NCDs” (and their synonyms) AND (“delivery of healthcare, integrated” OR a range of other terms representing integration) were used. Articles were included if they were descriptions or evaluations of a management or organisational change strategy made within LMICs, which aim to increase integration between TB and NCD management at the service delivery level. We performed a comparative analysis of key themes from these studies and organised the themes based on integration of service delivery options for TB and NCD services. Subsequently, these themes were used to reconfigure and update an existing framework for integration of TB and HIV services by Legido-Quigley and colleagues, which categorises the levels of integration according to types of services and location where services were offered. Additionally, we developed themes on the facilitators and barriers facing integrated service delivery models and mapped them to the World Health Organization’s (WHO) health systems framework, which comprises the building blocks of service delivery, human resources, medical products, sustainable financing and social protection, information, and leadership and governance. A total of 22 articles published between 2011 and 2021 were used, out of which 13 were cross-sectional studies, 3 cohort studies, 1 case–control study, 1 prospective interventional study, and 4 were mixed methods studies. The studies were conducted in 15 LMICs in Asia, Africa, and the Americas. Our synthesised framework explicates the different levels of service integration of TB and NCD services. We categorised them into 3 levels with entry into the health system based on either TB or NCDs, with level 1 integration offering only testing services for either TB or NCDs, level 2 integration offering testing and referral services to linked care, and level 3 integration providing testing and treatment services at one location. Some facilitators of integrated service include improved accessibility to integrated services, motivated and engaged providers, and low to no cost for additional services for patients. A few barriers identified were poor public awareness of the diseases leading to poor uptake of services, lack of programmatic budget and resources, and additional stress on providers due to increased workload. The limitations include the dearth of data that explores the experiences of patients and providers and evaluates programme effectiveness. Conclusions Integration of TB and NCD services encourages the improvement of health service delivery across disease conditions and levels of care to address the combined burden of diseases in LMICs. This review not only offers recommendations for policy implementation and improvements for similar integrated programmes but also highlights the need for more high-quality TB–NCD research.

show abstract

“…This study analyzed the epidemiology of drug-resistant TB in seven rural areas in Hangzhou (Yuhang, Fuyang, Linan, Tonglu, Jiande, Chunan, and Xiaoshan). Of all included patients, 76.96% (1 984/2578) were Hangzhou residents, and the proportion of previously treated patients was 25.02% (645/2 578), which was significantly lower than the data from other TB hospitals in China 8 . The results indicated a functioning local TB control program in Hangzhou, China.…”

mentioning

confidence: 58%

Drug-Resistant Mycobacterium tuberculosis Isolates from New and Previously Treated TB Patients in China, 2017-2019

Zeng

Jun

2021

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

INTRODUCTION: Mycobacterium tuberculosis (MTB) is a causative agent of tuberculosis (TB) that causes death worldwide. METHODS: MTB was subjected to phenotypic drug-susceptibility tests (DST), and drug-resistant genes were sequenced. RESULTS: Previously treated patients were more likely to have positive smear results and exhibit drug resistance. New patients were more likely to be mono SM-resistant and less likely to be INH- and RIF-resistant. The most common mutations were katG (S315T), rpoB (S450L), rpsL (K43R), and embB (M306V). CONCLUSIONS: The proportion of mono-SM-resistant TB among new patients was higher.

show abstract

<p>Resistance To First-Line Antituberculosis Drugs And Prevalence Of <em>pncA</em> Mutations In Clinical Isolates Of <em>Mycobacterium tuberculosis</em> From Zunyi, Guizhou Province Of China</p>

Cited by 9 publications

References 36 publications

Diabetes Mellitus and History of Tuberculosis Treatment as Risk Factors of Developing Multidrug-Resistant Tuberculosis at TB Polyclinic Dr. Soetomo General Hospital 2019 - 2020

Diabetes Mellitus and History of Tuberculosis Treatment as Risk Factors of Developing Multidrug-Resistant Tuberculosis at TB Polyclinic Dr. Soetomo General Hospital 2019 - 2020

Integrating tuberculosis and noncommunicable diseases care in low- and middle-income countries (LMICs): A systematic review

Drug-Resistant Mycobacterium tuberculosis Isolates from New and Previously Treated TB Patients in China, 2017-2019

Contact Info

Product

Resources

About